DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
Recommended Citation
Strober B, Sofen H, Imafuku S, Paul C, Gooderham M, Spelman L, Seo SJ, Passeron T, Kisa RM, Berger V, Vritzali E, Hoyt K, Colombo MJ, Banerjee S, Augustin M, Stein Gold LF, Alexis A, Thaçi D, Blauvelt A, Lebwohl M. DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS. Ann Rheum Dis 2024; 83:2039-2040.
Document Type
Conference Proceeding
Publication Date
6-1-2024
Publication Title
Ann Rheum Dis
Abstract
Background: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib was superior to placebo and apremilast in the global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials in psoriasis. [1] Deucravacitinib is being investigated in several immune-mediated diseases and has shown efficacy vs placebo in phase 2 trials in systemic lupus erythematosus (SLE) (NCT03252587) and psoriatic arthritis (PsA) (NCT03881059). The POETYK long-term extension (LTE) trial (NCT04036435) showed that deucravacitinib maintained long-term efficacy through 2 years, with no new safety signals. [2] Objectives: We report clinical efficacy up to 3 years (148 weeks) in the POETYK LTE trial in a subset of patients with plaque psoriasis who received continuous deucravacitinib from day 1 in the parent trials. Methods: In POETYK PSO-1 and PSO-2, patients were randomized 1:2:1 to placebo, deucravacitinib 6 mg once daily (QD), or apremilast 30 mg twice daily. At week 52, patients could enter the POETYK LTE trial and receive open-label deucravacitinib 6 mg QD. Deucravacitinib efficacy through week 148 was evaluated in patients from pooled POETYK PSO-1 and PSO-2 populations; these patients received continuous deucravacitinib from day 1, achieved ≥ 75% reduction from baseline in Psoriasis Area and Severity Index score (PASI 75) at week 16 (primary endpoint) or week 24 (peak response), and were enrolled in the POETYK LTE trial. Maintenance of response was assessed through the data cutoff (June 15, 2022); responses assessed included PASI 75 and ≥ 90% reduction from baseline in PASI (PASI 90). A static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with a ≥ 2-point improvement from baseline was assessed. Results: A total of 513 patients completed 52 weeks in the parent trials and received continuous deucravacitinib from day 1, including 313 patients (61.4%; 95% CI, 57.0-65.6) who achieved PASI 75 at week 16 and 336 patients (66.5%; 95% CI, 62.2-70.6) who achieved PASI 75 at week 24. Among these patients, PASI 75 response rates were maintained from weeks 52 to 148 (Table 1). PASI 90 response rates were maintained in > 50% of patients from the start of the POETYK LTE trial (Table 1). Response rates for sPGA score of 0/1 were maintained from weeks 52 to 148 (Table 1). Conclusion: Clinical efficacy was maintained for up to 148 weeks with continuous deucravacitinib in most patients who were week 16 and week 24 PASI 75 responders in the parent trials and enrolled in the POETYK LTE trial. These findings further support the long-term use of once-daily oral deucravacitinib as an effective treatment for patients with psoriasis.
Volume
83
First Page
2039
Last Page
2040
